Dr. Michael A. Papagikos
Claim this profileNHRMC Radiation Oncology - Supply
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
26 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage I
Stage II
2Non-Small Cell Lung Cancer
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Michael A. Papagikos is currently running
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
Recruiting2 awards Phase 31 criteria
More about Michael A. Papagikos
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael A. Papagikos has experience with
- Histrelin
- Bicalutamide
- Leuprolide
- Triptorelin
- Goserelin
- Flutamide
Breakdown of trials Michael A. Papagikos has run
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael A. Papagikos specialize in?
Michael A. Papagikos focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage I.
Is Michael A. Papagikos currently recruiting for clinical trials?
Yes, Michael A. Papagikos is currently recruiting for 2 clinical trials in Supply North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Michael A. Papagikos has studied deeply?
Yes, Michael A. Papagikos has studied treatments such as Histrelin, Bicalutamide, Leuprolide.
What is the best way to schedule an appointment with Michael A. Papagikos?
Apply for one of the trials that Michael A. Papagikos is conducting.
What is the office address of Michael A. Papagikos?
The office of Michael A. Papagikos is located at: NHRMC Radiation Oncology - Supply, Supply, North Carolina 28462 United States. This is the address for their practice at the NHRMC Radiation Oncology - Supply.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.